Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Novartis

Tracked across 54 events · 452 articles · First seen Apr 22, 2025 · Last active Sep 23, 2026

Sentiment
17
Attention
7
Events
54
Relationships
16
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 20
Business
Impact: Novartis announced the expansion of its community health programs to address gaps in heart disease and cancer care globally, which could positively impact its public image and long-term market position.
Apr 09, 2026 · 7 articles
6 75
Regulatory
Impact: Novartis received International — European Commission approval for its gene therapy Itvisma, expanding its market reach for spinal muscular atrophy treatments and reinforcing its position in gene therapy. This approval is a significant positive for the company.
Jul 02, 2026 · 7 articles
4 70
Tech
Impact: As the company presenting the new data, Novartis's immunology portfolio is highlighted, potentially boosting its market position and future revenue prospects. The positive clinical trial results for its key drugs could lead to increased investor confidence.
May 31, 2026 · 6 articles
6 70
Business
Impact: Novartis is acquiring Myricx Bio to strengthen its oncology pipeline with next-generation antibody-drug conjugates (ADCs) and novel NMTi payload mechanisms, expanding its options for cancer patients and potentially establishing a new class of ADC payloads.
Jul 05, 2026 · 21 articles
4 50
Business
Impact: Novartis transitions to private equity ownership, appoints new CEO and board, and will rebrand; the company gains focus and resources for growth.
Jul 29, 2026 · 6 articles
4 80
Regulatory
Impact: Novartis received FDA approval to expand Pluvicto's indication to mHSPC, nearly doubling the eligible patient population and reinforcing its leadership in radioligand therapy. This is expected to drive future revenue growth, though the stock dipped 1.45% on the announcement.
Jul 31, 2026 · 6 articles
4 70
Regulatory
Impact: Novartis is the patent holder and beneficiary of the court ruling, which protects its blockbuster drug Sacubitril/valsartan from generic competition in the UK, supporting its revenue and market position.
Aug 13, 2026 · 6 articles
4 -20
Business
Impact: Novartis paused eight Rap cell trials after three patient deaths, triggering a safety review. Despite this, shares rose 4% on positive Remibrutinib data.
Sep 01, 2026 · 7 articles
2 80
Business
On September 7, 2026, Novartis announced the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, along with related intellectual property rights, from Pfizer and Pfizer — Pfizer Products Inc. for a total consideration…
Impact: Acquirer of Minipress trademarks, expanding its cardiovascular portfolio; shares rose 2.9% on the announcement.
Sep 07, 2026 · 6 articles
4 -45
Business
Artisan Partners Asset Management, a top-20 shareholder in Swiss drugmaker Novartis, publicly called for a shake-up of the company's board to improve corporate governance and oversight of acquisitions. David Samra, managing director at Artisan Partners…
Impact: Central subject of the event; its shares suffered a record fall after back-to-back trial setbacks and it now faces public shareholder pressure for board and governance changes.
Sep 10, 2026 · 6 articles
6 -45
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Novartis is the central entity of the event; the del-desiran Phase III failure and prior pelacarsen setback erased roughly $30 billion in market value and intensified investor scrutiny of its M&A strategy and pipeline.
Sep 08, 2026 · 21 articles
2 25
Business
Boomray Pharmaceuticals Co., Ltd. announced on September 22, 2026 that it has entered into an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset. Under the terms, BoomRay…
Impact: Licensee acquiring exclusive global rights to the RLT asset; expands its radioligand therapy portfolio and oncology pipeline with external innovation at limited upfront cost.
Sep 22, 2026 · 6 articles
4 10
Business
Impact: Novartis settled a lawsuit with the estate of Henrietta Lacks over the unauthorized use of her cells, which were used to develop various medical advancements. This settlement resolves a significant legal and ethical challenge for Novartis.
Feb 26, 2026 · 7 articles
4 60
Business
Impact: Novartis, an innovative medicines company, is collaborating with the United Arab Emirates — Department of Health – Abu Dhabi to expand its global scientific expertise in genomics research and advanced therapies, potentially leading to new treatment developments and market opportunities.
Jun 26, 2026 · 6 articles
4 -30
Business
Impact: Novartis' pelacarsen trial failed its primary endpoint, a setback for its cardiovascular pipeline.
Sep 04, 2026 · 12 articles
6 20
Regulatory
Impact: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
4 60
Tech
Impact: Novartis, the manufacturer of Onasemnogene abeparvovec, views this approval as a milestone in patient care and a reflection of its commitment to neurology and expanding its focus into neuroimmunology, neurodegenerative disorders, and neuromuscular diseases.
Dec 20, 2025 · 6 articles
2 40
Business
Impact: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
6 30
International
Impact: Novartis is a key investor, announcing two U.S. projects: a biomedical research center in San Diego and a cancer-drug production facility in Texas.
Jun 07, 2026 · 7 articles
2 70
Tech
Impact: Co-funded the pilot and likely supplies treatment. Positive reputation and potential market expansion for SMA therapies.
Sep 01, 2026 · 10 articles
2 5
Regulatory
Chairs of nine European pharmaceutical companies published an open letter on their corporate websites on September 22, 2026, calling on the European Union and its member states to boost investment in the region's drug industry.…
Impact: A signatory of the open letter urging the European Union and member states to strengthen the region's pharmaceutical industry. The appeal is aimed at improving the investment and regulatory climate it operates in.
Sep 22, 2026 · 6 articles
4 70
Tech
Impact: Novartis partnered with Dr. Carl H. June, leading to the development and FDA approval of Tisagenlecleucel, the first CAR-T therapy, which significantly boosted the company's position in advanced cancer treatments.
Jun 16, 2026 · 8 articles
1 10
Business
Impact: Novartis participated in the symposium, demonstrating its commitment to green chemistry and sustainable manufacturing.
Jul 20, 2026 · 6 articles
4 -10
Business
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, comprising $1.65 billion upfront plus up to $700 million in contingent milestone payments. The upfront…
Impact: Dominant radiopharmaceutical player with Pluvicto and Lutathera faces a more vertically integrated competitor as Telix absorbs ITM's isotope supply and neuroendocrine tumor pipeline.
Sep 21, 2026 · 6 articles
2 -5
Regulatory
ANI Pharmaceuticals received final approval from the U.S. United States — Food and Drug Administration for its Abbreviated New Drug Application for Everolimus Tablets for Oral Suspension in 2mg, 3mg and 5mg strengths. The product…
Impact: Novartis' Afinitor Disperz faces new generic competition from ANI's approved Everolimus Tablets for Oral Suspension. The affected franchise is small relative to Novartis' overall business, so the financial impact is limited.
Sep 23, 2026 · 7 articles
6 60
Tech
Impact: Novartis is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments, showcasing the industry's move towards Pharma 4.0.
Apr 07, 2026 · 8 articles
4 -10
Regulatory
Impact: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.
Jul 07, 2026 · 6 articles
2 70
Business
Impact: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.
Jul 15, 2026 · 10 articles
4 5
Tech
Anthropic has quietly established a wet lab in the San Francisco Bay Area to conduct physical biology experiments, moving beyond computer-based in silico research into hands-on drug science. The lab's existence was confirmed by Eric…
Impact: Novartis CEO Shar Narasimhan sits on Anthropic's board, linking the pharma giant to Anthropic's AI drug efforts.
Sep 18, 2026 · 22 articles
7 -10
International
Impact: Novartis employed Jason Thomas, a pharmaceutical researcher who was found dead after disappearing, adding a pharmaceutical link to the broader pattern of mysterious deaths.
Apr 11, 2026 · 6 articles
+ 24 more events View on Dashboard
100 Novartis acquired trademarks PfizerNovartis India acquires...
100 Novartis announced trial failureNovartis del-desiran Phase...
95 Novartis failed late-stage studyNovartis del-desiran Phase...
90 Novartis failed late-stage studyArtisan Partners Urges...
70 Novartis disappointed investorsArtisan Partners Urges...
70 Novartis missed pipeline readoutsNovartis del-desiran Phase...
65 Novartis faced investor scrutinyNovartis del-desiran Phase...
50 Novartis committed acquisitionsNovartis del-desiran Phase...
40 Novartis reiterated full-year guidanceNovartis del-desiran Phase...
40 Novartis reaffirmed guidanceArtisan Partners Urges...
Amgen ↔ Novartis
Amgen ↔ Novartis
Roche ↔ Novartis
Roche ↔ Novartis
Sanofi ↔ Novartis
Sanofi ↔ Novartis
AstraZeneca ↔ Novartis
AstraZeneca ↔ Novartis
Switzerland ↔ Novartis
Switzerland ↔ Novartis
United States ↔ Novartis
United States ↔ Novartis
China ↔ Novartis
China ↔ Novartis
ERGEN INTELLIGENCE
Track Novartis live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.